Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients

Table 4 Prognostic factors of survival after tumor relapse (“survival after relapse”) based on a multiple Cox regression model (n = 63 patients)

Variable		Hazard ratio^a	95 % CI	p-value
Age at 1^st diagnosis	per year	1.03	1.00–1.05	0.04
EOR	CR vs. PR	0.76	0.41–1.40	0.64
TMZ at 1^st diagnosis	yes vs. no	0.32	0.15–0.71	0.005
Therapies other than BCNU at tumor recurrence	yes vs. no	0.56	0.30–1.02	0.06
MGMT promoter methylation	yes vs. no	0.89	0.51–1.53	0.66
BCNU	yes vs. no	0.48	0.26–0.89	0.02

^aA hazard ratio <1 (>1) indicates an effect in favor of the first (second) group
CI confidence interval, EOR extent of resection, CR complete resection, PR partial resection/biopsy

ISSN: 1471-2407